

### Aster DM Healthcare Limited

CIN: L85110KAZ008PLC147259  
 Registered Office: No.176, Sector Post, Sector-4, HSR Layout, Ward No.17A, Agar Extension, Bengaluru-560102, Karnataka, India. Tel: +91 484 6869699. Email: info@asterdmhealthcare.com Website: www.asterdmhealthcare.com

#### STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2022

(Amount in ₹ Crores except per share data)

Particulars	Consolidated				Standalone			
	For quarter ended 30-Jun-22 (Unaudited)	For quarter ended 31-Mar-22 (Audited)	For quarter ended 30-Jun-21 (Unaudited)	For quarter ended 31-Mar-21 (Audited)	For quarter ended 30-Jun-22 (Unaudited)	For quarter ended 31-Mar-22 (Audited)	For quarter ended 30-Jun-21 (Unaudited)	For quarter ended 31-Mar-21 (Audited)
Total Income	2,669.39	2,743.77	2,374.03	10,300.94	296.70	345.30	238.52	1,986.07
Net Profit (Loss) before tax	83.22	244.82	71.88	436.85	26.80	42.05	(7.42)	89.98
Net Profit (Loss) after tax	79.77	243.63	69.60	401.05	26.80	42.07	(7.42)	90.18
Total Comprehensive Income (Loss)	158.00	317.90	79.04	694.50	26.80	43.33	(7.42)	90.64
Equity Share Capital	497.27	497.22	497.11	497.22	497.27	497.22	497.11	497.22
Other Equity	-	-	-	3,056.78	-	-	-	2,457.99
Earnings per share (Face value of ₹10/- each)	Not Applicable/Not Annualised/Not Annualised	Not Annualised/Not Annualised/Not Annualised	Not Annualised/Not Annualised/Not Annualised	Not Annualised/Not Annualised/Not Annualised	Not Annualised/Not Annualised/Not Annualised	Not Annualised/Not Annualised/Not Annualised	Not Annualised/Not Annualised/Not Annualised	Not Annualised/Not Annualised/Not Annualised
Basic	1.38	4.65	0.89	10.58	0.60	1.26	(0.15)	1.81
Diluted	1.38	4.65	0.89	10.57	0.60	1.26	(0.15)	1.81

The unaudited consolidated and standalone financial results of the Company for the quarter ended June 30, 2022 have been reviewed by the Audit Committee of the Board on August 11, 2022 and approved by the Board of Directors at its meeting held on August 11, 2022.

The above is an extract of the detailed format of quarterly financial results filed with the Stock Exchanges under Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements (Regulations, 2015). The full format of the Quarterly financial statements is made available on the Company's website at <http://www.asterdmhealthcare.com/investorrelations/information> and stock exchange website at BSE <http://www.bseindia.com> and NSE <http://www.nseindia.com>. The Statement has been subjected to limited review by Deloitte Haskins & Sells, the statutory auditor of the Company. The review report of the auditor is appended.

For Aster DM Healthcare Limited  
 Dr. Aradhya Moghe, Chairman and Managing Director  
 Date: August 11, 2022

### ARTEM

Ph: +91-124-4511111; Fax: +91-124-4511111

CIN: L85110DL2004PLC126414

#### EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2022

(₹ in Lacs)

S. No.	Particulars	Quarter Ended		Year Ended
		30 Jun 22	30 Jun 21	
1	Total Income from Operations	16,723.32	12,228.50	55,480.12
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	1,061.24	635.35	3,718.48
3	Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary Items)	1,061.24	635.35	3,718.48
4	Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary Items)	826.61	378.76	3,140.15
5	Total Comprehensive Income for the period (comprising Profit for the period (after tax) and Other Comprehensive Income (after tax))	818.24	388.90	3,108.68
6	Pay-up Equity Share Capital (Face Value ₹1/-each)	1,328.27	1,323.77	1,323.77
7	Reserves (excluding Revaluation Reserve)	-	-	27,925.53
8	Earning per Equity Share (Face Value ₹1/-each)	0.64*	0.29*	2.40
	(a) Basic	0.61*	0.28*	2.29
	(b) Diluted			
	(* Not annualised)			

The above is an extract of the detailed format of unaudited financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results (Consolidated/ Standalone) are available on the Stock Exchange websites (National Stock Exchange of India Limited ([www.nseindia.com](http://www.nseindia.com)) & BSE Limited ([www.bseindia.com](http://www.bseindia.com))) and on the company's website ([www.artemshospitals.com](http://www.artemshospitals.com)).

The above results for the quarter ended June 30, 2022 were reviewed by the Audit Committee meeting held on August 11, 2022 and approved by the Board of Directors meeting held on August 11, 2022. The Statutory Auditors have expressed an unmodified conclusion on the above results and the above financial results have been prepared in accordance with the companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as prescribed under Section 133 of the Companies Act 2013, and the other recognised accounting practices and policies to the extent applicable.

For and on behalf of the Board of Directors of Artemis Medicare Services Limited  
 Onkar Kamwar, Chairman  
 Place: Gurugram  
 Date: August 11, 2022

### BADVE ENGINEERING LIMITED

CIN: U73100MH1906PLC102827  
 Registered Office: Plot No. D-36, MIDC Area, Wajuli, Aurangabad - 431133.  
 Website: [www.badvegroup.com](http://www.badvegroup.com)

#### UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30<sup>th</sup> JUNE 2022

(All amounts in ₹ Crores, except per share data)

Sr. No.	Particulars	Standalone			Consolidated		
		Quarter ended 30 <sup>th</sup> June, 2022 (Unaudited)	Quarter ended 31 <sup>st</sup> March, 2022 (Audited)	Year ended 30 <sup>th</sup> June, 2022 (Audited)	Quarter ended 30 <sup>th</sup> June, 2022 (Unaudited)	Quarter ended 31 <sup>st</sup> March, 2022 (Audited)	Year ended 30 <sup>th</sup> June, 2022 (Audited)
1	Total income from operations	1,250.53	1,436.34	4,322.78	1,458.55	1,557.74	5,412.41
2	Net Profit/(Loss) for the period (before tax, exceptional and/or extraordinary items)	74.40	86.59	292.73	82.43	91.23	308.73
3	Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary Items)	74.40	86.59	292.73	82.43	91.23	308.73
4	Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary Items)	61.50	78.96	247.13	69.54	72.10	283.13
5	Total Comprehensive Income for the period (comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax))	59.83	64.31	268.41	67.66	65.43	294.42
6	Pay-up Equity Share Capital	20.34	20.34	20.34	20.34	20.34	20.34
7	Reserves (excluding Revaluation Reserve)	1,681.31	1,622.99	1,622.09	1,723.39	1,653.83	1,653.83
8	Securities Premium Account	62.77	62.77	62.77	62.77	62.77	62.77
9	Net worth	1,762.96	1,842.42	1,845.43	1,782.79	1,841.12	1,841.12
10	Payable Debt Capital/Outstanding Debt	2,548.89	2,591.96	2,591.96	2,593.78	2,597.96	2,597.96
11	Outstanding Redeemable Preference Shares	-	-	-	-	-	-
12	Debt Equity Ratio	1.50	1.58	1.58	1.55	1.55	1.55
13	Earnings Per Share of ₹ 10/- each (For continuing or discontinued operations)	30.00	35.00	121.00	34.00	35.00	120.00
	1. Basic	30.00	35.00	121.00	34.00	35.00	120.00
	2. Diluted	30.00	35.00	121.00	34.00	35.00	120.00
14	Capital Redemption Reserve	-	-	-	-	-	-
15	Debiture Redemption Reserve	-	-	-	-	-	-
16	Debt Service Coverage Ratio	1.60	1.66	1.68	1.71	1.70	2.00
17	Interest Service Coverage Ratio	3.39	3.47	3.50	2.49	2.56	2.97
18	Current Ratio	1.34	1.37	1.37	1.43	1.38	1.38
19	Long Term Debt to Working Capital	2.82	2.71	2.71	2.14	2.54	2.54
20	Bad Debts to Accounts Receivable Ratio	-	-	-	-	-	-
21	Current Liability Ratio	0.50	0.47	0.47	0.50	0.48	0.48
22	Total Debt to Total Assets Ratio	0.45	0.51	0.51	0.49	0.50	0.50
23	Debtors Turnover Ratio	7.20	8.23	7.23	5.97	6.81	6.96
24	Inventory Turnover Ratio	11.52	12.85	11.16	12.69	13.84	11.42
25	Operating Margin (%)	17.5%	14.8%	15.9%	15.1%	13.8%	14.2%
26	Net Profit Margin (%)	5.1%	5.2%	5.2%	4.8%	4.8%	5.0%

The above is an extract of the detailed format of unaudited quarterly financial results filed with the BSE Limited (stock exchange), under Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"). The full format of the unaudited quarterly financial results are available on the Company's website at <http://www.badvegroup.com> and on the website of the Stock Exchange i.e. [www.bseindia.com](http://www.bseindia.com).

The above unaudited financial results of the Company were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 12th August 2022. The results for quarter ended June 30, 2022 have been reviewed by the Statutory Auditors of the Company and have provided their Limited Review Report on the same.

For the other line items referred in the Regulation 52 (4) of the Listing Regulations, the pertinent disclosures have been made to the BSE Limited (stock exchange) and can be accessed on the URL: <http://www.badvegroup.com> and <http://www.bseindia.com>.

For and on behalf of the Board of Directors  
 Shikant Bhatia, Managing Director  
 Date: 12<sup>th</sup> August 2022  
 DIN: 06295695

#### EXTRACT OF STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2022

(₹ in million, except per share data)

S. No.	Particulars	Quarter ended		Year ended
		30-06-2022	31-03-2022	
1	Total Revenue from Operations	1013.55	1812.69	5300.49
2	Net Profit/(Loss) for the period (before Tax, Exceptional)	301.38	754.81	139.41
3	Net Profit/(Loss) for the period before Tax, (after Exceptional)	301.38	754.81	139.41
4	Net Profit/(Loss) for the period after Tax (after Exceptional)	252.49	462.11	77.39
5	Total Comprehensive Income for the period (comprising Profit/(Loss) for the period (after Tax) and Other Comprehensive Income (after tax))	(7.38)	1.17	0.04
6	Equity Share Capital	160.97	160.97	146.37
7	Other Equity	6241.02	5942.63	2663.80
8	Earning per share (of ₹ 2/- each) (not annualized)	3.14	5.74	0.96
	1. Basic	3.14	5.74	0.96
	2. Diluted			

The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchange websites ([www.bseindia.com](http://www.bseindia.com)), ([www.nseindia.com](http://www.nseindia.com)) and Company's Website ([www.supriyalifescience.com](http://www.supriyalifescience.com)).

For Supriya Lifescience Limited  
 Satiya Vagh, Whole Time Director  
 Place: Mumbai  
 Date: August 12, 2022  
 DIN: 08491410

#### Supriya Lifescience Limited

CIN: L5901MH0089PLC180452  
 207/208, Ujijog Bhawan, Sonawala Road, Orangeri (East), Mumbai - 400083.  
 Tel: +91 22 40332727; E-mail: [tdg@supriyalifescience.com](mailto:tdg@supriyalifescience.com); Website: [www.supriyalifescience.com](http://www.supriyalifescience.com)

#### EXTRACT OF STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2022

(₹ in Crores)

ISIN No.	Debt Series	Principal Amount	Principal Due Date	Previous Interest Payment due date	Previous date of Interest Payment	Next due date for Interest Payment	Next due amount of Interest Payable
INE994W029	BEI-8.50%-2-23-FVT Tranche 2 Series A	50.00	2 <sup>nd</sup> June, 2023	31 <sup>st</sup> March, 2022	28 <sup>th</sup> March, 2022	30 <sup>th</sup> Sept, 2022	2.38
INE994W037	BEI-8.50%-2-23-FVT Tranche 2 Series B	25.00	2 <sup>nd</sup> June, 2023	31 <sup>st</sup> March, 2022	28 <sup>th</sup> March, 2022	30 <sup>th</sup> Sept, 2022	1.19
INE994W045	BEI-8.50%-23-4-24-FVT Tranche 3	50.00	23 <sup>rd</sup> Aug, 2024	31 <sup>st</sup> March, 2022	28 <sup>th</sup> March, 2022	30 <sup>th</sup> Sept, 2022	2.37
INE994W052	BEI-8.50%-23-12-24-FVT Tranche 4	50.00	23 <sup>rd</sup> Dec, 2024	-	-	23 <sup>rd</sup> Dec, 2022	4.75
<b>Total</b>		<b>235.00</b>					<b>13.55</b>

There is no default in payment of interest and principal on NCDs. The Company has paid interest up to March 31, 2022 on outstanding NCDs, on March 28, 2022 itself. As on June 30, 2022, the details of principal amount, principal due date, previous interest payment due date, previous date of interest payment, next due date of interest payment and next interest payable are provided below:

#### Supriya Lifescience Limited

CIN: L5901MH0089PLC180452  
 207/208, Ujijog Bhawan, Sonawala Road, Orangeri (East), Mumbai - 400083.  
 Tel: +91 22 40332727; E-mail: [tdg@supriyalifescience.com](mailto:tdg@supriyalifescience.com); Website: [www.supriyalifescience.com](http://www.supriyalifescience.com)

#### EXTRACT OF STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2022

(₹ in million, except per share data)

S. No.	Particulars	Quarter ended		Year ended
		30-06-2022	31-03-2022	
1	Total Revenue from Operations	1013.55	1812.69	5300.49
2	Net Profit/(Loss) for the period (before Tax, Exceptional)	301.38	754.81	139.41
3	Net Profit/(Loss) for the period before Tax, (after Exceptional)	301.38	754.81	139.41
4	Net Profit/(Loss) for the period after Tax (after Exceptional)	252.49	462.11	77.39
5	Total Comprehensive Income for the period (comprising Profit/(Loss) for the period (after Tax) and Other Comprehensive Income (after tax))	(7.38)	1.17	0.04
6	Equity Share Capital	160.97	160.97	146.37
7	Other Equity	6241.02	5942.63	2663.80
8	Earning per share (of ₹ 2/- each) (not annualized)	3.14	5.74	0.96
	1. Basic	3.14	5.74	0.96
	2. Diluted			

The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchange websites ([www.bseindia.com](http://www.bseindia.com)), ([www.nseindia.com](http://www.nseindia.com)) and Company's Website ([www.supriyalifescience.com](http://www.supriyalifescience.com)).

For Supriya Lifescience Limited  
 Satiya Vagh, Whole Time Director  
 Place: Mumbai  
 Date: August 12, 2022  
 DIN: 08491410